US2006063740A1PendingUtilityA1

Method for inhibiting bone resorption

66
Individually held — no corporate assignee on recordPriority: Jul 22, 1997Filed: Nov 14, 2005Published: Mar 23, 2006
Est. expiryJul 22, 2017(expired)· nominal 20-yr term from priority
Inventors:Anastasia DaifotisArthur SantoraA. Yates
A61K 31/675A61K 31/66A61K 31/663
66
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

Disclosed are methods for inhibiting bone resorption in mammals while minimizing the occurrence of or potential for adverse gastrointestinal effects. Also disclosed are pharmaceutical compositions and kits for carrying out the therapeutic methods disclosed herein.

Claims

exact text as granted — not AI-modified
1 . A method for inhibiting bone resorption in a mammal, said method comprising orally administering to said mammal a pharmaceutically effective amount of a bisphosphonate as a unit dosage according to a continuous schedule having a dosing interval selected from the group consisting of once-weekly dosing, twice-weekly dosing, biweekly dosing, and twice-monthly dosing.  
     
     
         2 . A method according to  claim 1  wherein said bisphosphonate is selected from the group consisting of alendronate, cimadronate, clodronate, tiludronate, etidronate, ibandronate, risedronate, piridronate, pamidronate, zolendronate, pharmaceutically acceptable salts thereof, and mixtures thereof.  
     
     
         3 . A method according to  claim 1  wherein said bisphosphonate is selected from the group consisting of alendronate, pharmaceutically acceptable salts thereof, and mixtures thereof.  
     
     
         4 . A method according to  claim 3  wherein said pharmaceutically acceptable salt is alendronate monosodium trihydrate.  
     
     
         5 . A method according to  claim 4  wherein said mammal is a human.  
     
     
         6 . A method for treating osteoporosis in a mammal in need of such treatment, said method comprising orally administering to said mammal a pharmaceutically effective amount of a bisphosphonate as a unit dosage according to a continuous schedule having a dosing interval selected from the group consisting of once-weekly dosing, twice-weekly dosing, biweekly dosing, and twice-monthly dosing.  
     
     
         7 . A method according to  claim 6  wherein said mammal is a human.  
     
     
         8 . A method according to  claim 7  wherein said dosing interval is once-weekly and said unit dosage comprises about 70 mg of alendronate monosodium trihydrate, on an alendronic acid active basis.  
     
     
         9 . A method according to  claim 7  wherein said dosing interval is twice-weekly and said unit dosage comprises about 35 mg of alendronate monosodium trihydrate, on an alendronic acid active basis.  
     
     
         10 . A method according to  claim 7  wherein said dosing interval is biweekly and said unit dosage comprises about 140 mg of alendronate monosodium trihydrate, on an alendronic acid active basis.  
     
     
         11 . A method according to  claim 7  wherein said dosing interval is twice-monthly and said unit dosage comprises about 140 mg of alendronate monosodium trihydrate, on an alendronic acid active basis.  
     
     
         12 . A method for preventing osteoporosis in a mammal in need of such treatment, said method comprising orally administering to said mammal a pharmaceutically effective amount of a bisphosphonate as a unit dosage according to a continuous schedule having a dosing interval selected from the group consisting of once-weekly dosing, twice-weekly dosing, biweekly dosing, and twice-monthly dosing.  
     
     
         13 . A method according to  claim 12  wherein said mammal is a human.  
     
     
         14 . A method according to  claim 13  wherein said dosing interval is once-weekly and said unit dosage comprises about 35 mg of alendronate monosodium trihydrate, on an alendronic acid active basis.  
     
     
         15 . A method according to  claim 13  wherein said dosing interval is twice-weekly and said unit dosage comprises about 17.5 mg of alendronate monosodium trihydrate, on an alendronic acid active basis.  
     
     
         16 . A method according to  claim 13  wherein said dosing interval is biweekly and said unit dosage comprises about 70 mg of alendronate monosodium trihydrate, on an alendronic acid active basis.  
     
     
         17 . A method according to  claim 13  wherein said dosing interval is twice-monthly and said unit dosage comprises about 70 mg of alendronate monosodium trihydrate, on an alendronic acid active basis.  
     
     
         18 . A method for treating abnormal bone resorption in a human in need of such treatment comprising orally administering to said human a unit dosage of a bisphosphonate, said unit dosage comprising from about 17.5 mg to about 140 mg, on an alendronic acid basis, of a bisphosphonate selected from the group consisting of alendronate, pharmaceutically acceptable salts thereof, and mixtures thereof.  
     
     
         19 . A method according to  claim 18  wherein said unit dosage comprises about 35 mg of the bisphosphonate.  
     
     
         20 . A method according to  claim 18  wherein said unit dosage comprises about 70 mg of the bisphosphonate.  
     
     
         21 . A method according to  claim 20  wherein said unit dosage is administered once-weekly.  
     
     
         22 . A method according to  claim 18  wherein said unit dosage comprises about 140 mg of the bisphosphonate.  
     
     
         23 . The method in accordance with  claim 8 , comprising orally administering to said human a unit dosage of a bisphosphonate, said unit dosage comprising from about 8.75 mg to about 70 mg, on an alendronic acid basis, of a bisphosphonate selected from the group consisting of alendronate, pharmaceutically acceptable salts thereof, and mixtures thereof, on an alendronic acid active weight basis.  
     
     
         24 . A method according to  claim 23  wherein said unit dosage comprises about 17.5 mg of the bisphosphonate.  
     
     
         25 . A method according to  claim 23  wherein said unit dosage comprises about 35 mg of the bisphosphonate.  
     
     
         26 . A method according to  claim 25  wherein said unit dosage is administered once-weekly.  
     
     
         27 . A method according to  claim 23  wherein said unit dosage comprises about 70 mg of the bisphosphonate.  
     
     
         28 . (canceled)  
     
     
         29 . (canceled)  
     
     
         30 . A pharmaceutical composition comprising about 70 mg, on an alendronic acid active basis, of a bisphosphonate selected from the group consisting of alendronate, pharmaceutically acceptable salts thereof, and mixtures thereof.  
     
     
         31 . (canceled)  
     
     
         32 . (canceled)  
     
     
         33 . A method for inhibiting bone resorption in a mammal, said method comprising orally administering to said mammal a pharmaceutically effective amount of a bisphosphonate as a unit dosage according to a continuous schedule having a periodicity from about once every 3 days to about once every 16 days.  
     
     
         34 . The method in accordance with  claim 12 , comprising orally administering to said human about 70 mg of alendronate monosodium trihydrate, on an alendronic acid active basis, as a unit dosage according to a continuous schedule having a dosing interval of once-weekly.

Join the waitlist — get patent alerts

Track US2006063740A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.